The Veterinary Cancer Center, Norwalk, CT, USA.
VCA, Inc, Los Angeles, CA, USA.
Top Companion Anim Med. 2022 Jan-Feb;46:100616. doi: 10.1016/j.tcam.2021.100616. Epub 2021 Dec 2.
We evaluated the effect of oligo fucoidan (Laminina Japonica) derived from oceanic brown seaweed on the quality of life in dogs with cancer undergoing chemotherapy in a double-blinded case control study. Included in this prospective study were 100 dogs with a confirmed diagnosis of cancer that were being treated with chemotherapy. Dogs were randomly assigned to be treated with oligo fucoidan (treated group; n = 68) or placebo (placebo group; n = 32). Dogs were evaluated every 2-3 weeks for 3 months with a complete blood count (CBC) and serum biochemistry profile, and a complete history and physical examination by blinded clinicians at The Veterinary Cancer Center. The owners of the dogs enrolled in the study were required at each visit to complete a Quality-of-Life Questionnaire specifically designed for cancer-bearing veterinary patients. The owners were also blinded as to whether their dog was receiving oligo fucoidan or placebo. There were no significant differences between the CBC parameters or the serum biochemical parameters of the dogs in the treated and placebo-controlled groups. There was no significant difference in the median quality of life scores between the 2 cohorts, however, when evaluating the individual quality of life metrics, 5 out of the 23 metrics showed statistically significant improvement, and none of the quality-of-life metrics declined in the oligo fucoidan group as compared to the placebo group. All of the dogs that had a positive change in overall quality of life scores were dogs that received oligo fucoidan. There were minimal adverse side effects of giving the oligo fucoidan to dogs. Treatment with oligo fucoidan was safe and improved some of the quality-of-life metrics in dogs who were being treated with chemotherapy for cancer.
我们在一项双盲病例对照研究中评估了海洋褐藻来源的低聚褐藻糖胶（Laminina Japonica）对接受化疗的癌症犬生活质量的影响。这项前瞻性研究纳入了 100 只经确诊患有癌症且正在接受化疗的犬。将这些犬随机分为接受低聚褐藻糖胶治疗组（n=68）或安慰剂组（n=32）。在 3 个月的时间里，每 2-3 周通过盲法临床医生对犬进行一次全血细胞计数（CBC）和血清生化分析，以及全面的病史和体格检查。参加研究的犬的主人需要在每次就诊时完成一份专为癌症宠物患者设计的生活质量问卷。主人也不知道他们的狗是接受低聚褐藻糖胶还是安慰剂。治疗组和安慰剂对照组的犬的 CBC 参数或血清生化参数没有显著差异。两组的中位生活质量评分无显著差异，但在评估个别生活质量指标时，23 项指标中有 5 项有统计学意义的改善，且与安慰剂组相比，低聚褐藻糖胶组的生活质量指标没有下降。所有整体生活质量评分有改善的犬均接受了低聚褐藻糖胶治疗。给予犬低聚褐藻糖胶的副作用极小。在接受化疗治疗癌症的犬中，使用低聚褐藻糖胶治疗是安全的，并改善了一些生活质量指标。
